ZYME: FDA approval, pipeline progress, and strategic buybacks drive a hybrid royalty and R&D model
FDA approval of zanidatamab and a robust pipeline position the company for significant royalty and milestone revenues, with additional late-stage assets and innovative R&D programs advancing. Strategic share buybacks, acquisitions, and global partnerships underpin a hybrid business model focused on…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.